Meta Pixel

News and Announcements

Mobilicom (ASX: MOB) completes $3.725M placement of new shares

  • Published April 15, 2019 12:00AM UTC
  • Publisher Wholesale Investor
  • Categories Company Updates

Highlights

  • Mobilicom Limited has successfully completed a $3.725m placement of new shares.
  • The placement will assist to accelerate Mobilicom’s expansion and large projects with key partners including Airbus, Yuneec and the Israel Innovation Authority.
  • The placement of the $3.725 million ordinary new shares was conducted at $0.10 per share.

Mobilicom Limited has successfully completed a $3.725m placement of new shares with participation from new and existing investors across Australia and international markets, including Mobilicom’s Non-Executive Director Mr Jon Brett. The placement of ordinary new shares was conducted at $0.10 per share.

The placement will assist to accelerate Mobilicom’s expansion and large projects with key partners including Airbus, Yuneec and the Israel Innovation Authority. It will additionally fund further business development in items such as Mobilicom’s new drone upgrade, operating costs, R&D and sales and marketing activities.

 

About Mobilicom Limited (ASX: MOB)

Mobilicom designs, develops and markets solutions for mission-critical and remote mobile private communication networks without the need for, or use of, any existing infrastructure. Mobilicom’s products and technology merge 4G communication with Mobile MESH technologies into a unified solution, with several product families that have been commercially deployed. Mobilicom’s SkyHopper entity targets the Professional, Commercial and Industrial UAV market.

Register Interest

Capital Insights
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship

From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.

Capital Insights
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer

In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]

Capital Insights
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts

As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.

Join over 45,000+ sophisticated investors

Join Now